Nephrology, Dialysis, Transplantation

Sparsentan - SGLT2 inhibitor combination therapy in trials of IgA nephropathy

By Isabelle M. Ayoub, Gabriela Alperovich, Radko Komers, Sydney Chi Wai Tang

Trial in peopleInterventions

The paper

Isabelle M. Ayoub, Gabriela Alperovich, Radko Komers, Sydney Chi Wai Tang

The Ohio State University; Queen Mary Hospital

Nephrology, Dialysis, Transplantation, 11 Sep 2026

doi.org/10.1093/ndt/gfag211 PubMed 42726023

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance